Steven D. Goldberg, San Diego, CA (US); Douglas C. Behenna, San Juan Capistrano, CA (US); Deane Gordon, San Diego, CA (US); Luke E. Hanna, San Diego, CA (US); Steven A. Loskot, San Diego, CA (US); Stefan McCarver, San Diego, CA (US); Steven P. Meduna, San Diego, CA (US); Brock T. Shireman, Poway, CA (US); Alexander E. Valdes, San Diego, CA (US); Jennifer D. Venable, Solana Beach, CA (US); and Dongpei Wu, San Diego, CA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Sep. 26, 2022, as Appl. No. 17/935,329.
Claims priority of provisional application 63/371,910, filed on Aug. 19, 2022.
Claims priority of provisional application 63/273,407, filed on Oct. 29, 2021.
Claims priority of provisional application 63/248,563, filed on Sep. 27, 2021.
Prior Publication US 2023/0147458 A1, May 11, 2023
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01)
24 Claims
1. A compound or a pharmaceutically acceptable salt thereof, having a formula selected from the group consisting of:
